PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
Study sponsor: CytomX Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2020-05-21Actual
Enrollment · participants3Actual
Source updated2025-12-26Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.